Plaque Volume Over Stenosis Degree

Paradigms are bound to eventually change. After years blinded by stenosis degree, plaque volume has proven to be a better predictor of cardiovascular events and death. Thus, patients with similar degrees of atherosclerosis burden have a similar prognosis, regardless of their lesions being obstructive or not.

El volumen de placa por sobre el grado de estenosis

The aim of this work was to assess whether obstructive disease has an additional predictive value beyond its association with the total number of calcified atherosclerotic lesions evaluated by tomography.

This analysis, recently published in JACC, included 23,759 symptomatic patients diagnosed by angiography. Major cardiovascular events (infarction, stroke, and all-cause mortality) were stratified by atherosclerotic burden and number of affected vessels.

After a median follow-up of 4.3 years, 1054 patients experienced their first cardiovascular event. The event rate increased with both higher calcium scores and higher number of affected vessels. With a calcium score of 0, the event rate was 6.2 patients per 1000, while a >1000 score indicated a risk of 42.3 patients per 1000.

Having 1 affected vessel provided a similar risk of events than a calcium score of 0 (6.1 patients per 1000), while having all 3 vessels affected was not as severe as a calcium score >1000 (34.7 patients per 1000).


Read also: Sapien 3 Performs Well in “Jobs” for Which It Is Not Designed.


After stratifying patients into 5 groups according to their calcium score (0, 1-99, 100-399, 400-1000, and >1000), the presence of obstructive disease was not associated with a higher risk when compared with patients without obstructive disease.

Conclusion

Plaque volume, and not stenosis per se, is the best predictor for cardiovascular events and death.

j-jacc-2020-10-021free

Original title: Impact of Plaque Burden Versus Stenosis on Ischemic Events in Patients With Coronary Atherosclerosis.

Reference: Martin Bødtker Mortensen et al. J Am Coll Cardiol 2020;76:2803–13 https://doi.org/10.1016/j.jacc.2020.10.021.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....